Ligand Pharmaceuticals is forking out $31.2 million up front to acquire CyDex Pharmaceuticals to accelerate its financial growth, expand the portfolio, and provide a drug reformulation platform.
The rationale for the deal is fairly clear. By acquiring CyDex, Ligand's 2011 revenue is projected to more than double...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
